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Summary 
Human interferon-inducible protein 10 (IP-10),  a member of the ot chemokine family, inhibits 
bone marrow colony formation, has antitumor activity in vivo, is chemoattractant for human 
monocytes and T  cells, and promotes T  cell adhesion to endothelial cells. Here we report that 
IP-10 is a potent inhibitor of angiogenesis in vivo.  IP-10 profoundly inhibited basic  fibroblast 
growth factor-induced neovascularization of Matrigel (prepared by H.  K. Kleinman) injected 
subcutaneously into athymic mice. In addition, IP-10, in a dose-dependent fashion, suppressed 
endothelial cell differentiation into tubular capillary structures in vitro. IP-10 had no effect on 
endothelial cell growth, attachment, and migration as assayed in vitro. These results document 
an important biological property of IP-10 and raise the possibility that IP-10 may participate 
in the regulation of angiogenesis during inflammation and tumorigenesis. 
ngiogenesis, the process of generating new blood vessels 
to neovascularization,  during repro-  leading  is essential 
duction, embryonic development, tissue and organ growth, 
and wound healing (1). Unbalanced neovascularization is be- 
lieved to contribute to the pathogenesis of certain disease states, 
such as arthritis, psoriasis, hemangiomas, diabetic retinopathy, 
and retrolental fibroplasia,  and to allow tumor growth and 
metastasis to occur (1). Tumor cells must attract new vessels 
to expand locally and produce metastasis (1, 2). Thus, anglo- 
genesis inhibitors might be developed into effective anticancer 
drugs. 
Several compounds have been reported to inhibit endothelial 
cell proliferation in various experimental systems, including 
TGF-B (3), thrombospondin (4), IL-1 (5), IFN-3' and -o~ (6), 
tissue inhibitor  of metalloproteinase  1  (7),  platelet  factor 
(PF) 1 4 (8),  protamine (9), and fumagillin (10). IFN-ot and 
1 Abbreviations used in this paper: bFGF, basic fibroblast growth factor; 
ECGS, endothelial cell growth supplement; FBHE, fetal bovine heart 
endothelial  cells; HUVEC, human umbilical  vein  endothelial  cells; IP-10, 
interferon-inducible  protein 10; MCAF, macrophage  chemotactic  and ac- 
tivating factor; Mig, monokine  induced by IFN-3q PF, platelet factor; 
R.ANTES, regulated  on activation, normal  T cell expressed  and secreted. 
a  fumagillin  derivative,  AGM-1470,  have reached clinical 
testing (2). 
Recently, we have reported on an experimental athymic 
mouse model in which regression of human Burkitt's lym- 
phoma is induced by intratumor inoculation of EBV-immor- 
talized human B cells (11). Extensive central necrosis associated 
with endothelial cell damage and intravascular thrombosis 
often distal to the necrotic tumor tissue is typical of regressing 
tumors (11). This suggested that tissue ischemia may be cen- 
tral to tumor regression and raised the possibility that un- 
balanced angiogenesis might be responsible for regression of 
Burkitt's lymphoma in this system (11). Analysis of murine 
cytokine expression showed that IL-6, TNF-ot, and interferon- 
inducible protein 10 (IP-10), but not other cytokines, are ex- 
pressed at higher levels by regressing tumors compared with 
progressing tumors (11). Because the biological functions of 
IP-10 are incompletely understood, we have tested the possi- 
bility that IP-10 might function as an inhibitor of angiogen- 
esis and might contribute to tumor regression. 
Materials and Methods 
Mice, Cells, Reagents, and Cytokines.  4-6-wk-old female  BALB/c 
nu/nu mice (Charles River Laboratories, Wilmington, MA, or Na- 
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MD)  maintained  in  pathogen-limited  conditions  were used 
throughout. Matrigel was extracted by H. K. Kleinman from the 
Englebreth-Holm-Swarm  tumor  as  previously described (12). 
Recombinant human Ipol0 (0.06 endotoxin U/gg, Pepro Tech, Inc., 
Rocky Hill, NJ) was either purchased or provided by the National 
Cancer Institute. TGF-B was obtained from R&D Systems (Min- 
neapolis, MN). The human monokine induced by IFN-3' (Mig) 
protein  was  the mature,  103-amino acid recombinant protein 
purified from an overexpressing Chinese hamster ovary cell line. 
The purification and characterization  of Mig will be described  else- 
where (Liao, F., R. Rabin, L. Koniaris, P. Vanguri, J. Yannelli, 
and J. Farber, manuscript in preparation). Mig concentration was 
determined using the Bradford assay  (Bio-Rad Laboratories, Rich- 
mond, CA) standardized  with BSA. Recombinant human IL-8  was 
obtained from BioSource, International (Camarillo, CA). Recom- 
binant  human  macrophage chemotactic  and  activating  factor 
(MCAF) and recombinant human regulated on activation, normal 
T cell  expressed, and secreted (RANTES) were obtained from Pepro 
Tech, Inc., and recombinant  human PF-4 was a gift of  Dr. T. Maione 
(Repligen Co., Cambridge, MA). Fetal bovine heart endothelial 
cells (FBHE; American Type Culture Collection, Rockville, MD) 
were grown in DMEM (Biofluids,  Inc., Rockville, MD) containing 
10% heat-inactivated fetal bovine serum (Intergen Co., Purchase, 
NY), 100 ng/ml basic fibroblast growth factor (bFGF) (R&D Sys- 
tems), and 5/xg/ml gentamicin (Sigma Chemical Co., St. Louis, 
MO).  Human umbilical vein endothelial cells (HUVEC),  from 
American Type Culture  Collection or provided by the National 
Institute of Dental Research (National Institutes of Health), were 
maintained in RPMI 1640 medium (Gibco BILL, Gaithersburg, 
MD), 15% FBS, 20 U/ml porcin ,~o~v~i~.-e-free  heparin (Squibb- 
Marsam, Inc., Cherry Hill, NJ), and 100 gg/ml endothelial cell 
growth supplement (ECGS; a crude extract of  bovine neural tissue 
containing bFGF and acidic FGF, Calbiochem-Novabiochem  Corp., 
La Jolla, CA). H5V, a murine heart endothelioma cell line, was 
a gift from Dr. A. Mantovani  (Instituto di Ricerche  Farmacologiche, 
Milan, Italy) (13). CD3-21, a murine pulmonary microvascular  en- 
dothelial cell line, was kindly provided by Dr. C. Diglio (Wayne 
State University, Detroit,  MI) (14). Both H5V and CD3-21 cells 
were grown in DMEM,  10% FBS, and 5/zg/ml gentamicin. 
In Vivo Matrigel Assay.  This assay was performed as described 
(15). Briefly, Matrigel (liquid at 4~  was mixed with 150 ng/ml 
bFGF alone or in combination with IP-10, TGF-~,  II:8, Mig, 
RANTES, or MCAF, each at a final concentration of 400 ng/ml. 
Matrigel alone or with bFGF, or with bFGF plus the test cytokine 
(total vol 0.5 ml), was injected subcutaneously into the midab- 
dominal region of the BALB/c nude mouse. After injection, the 
Matrigel polymerized to form a plug. After 7 d, the animals were 
killed, and the Matrigel plugs were removed together with the 
abstract epidermis and dermis, fixed in 10% neutral buffered for- 
malin solution (Sigma Chemical Co.), and embedded in paraffin. 
Histological sections were stained with Masson's trichrome. The 
vessel area in the histological sections was measured using a com- 
puterized digital analyzer  (Optomax, Hollis, NH) as described (15). 
The mean area per field (x 103 gm  2) from 15 fields (20 x ) was cal- 
culated. 
CellProliferation.  FBHE,  HUVEC, H5V, and CD3-21 cells  were 
used routinely before the 15th passage. After trypsinization, the 
cells were plated in triplicate cultures of 1 x  103 or 8  x  103 cells 
in 0.2 ml complete medium with or without additives  in a 96-well 
flat-bottom plate. The plates were incubated for 1-7 d. DNA syn- 
thesis was determined by [3H]thymidine deoxyribose uptake (0.5 
/~Ci/well, 6.7 Ci/mmol; New England Nuclear, Boston, MA) 
during the last 6 or 18 h of  culture. Cells were detached  by freezing 
and thawing. 
Cell Attachment Assay.  This assay  was performed as described 
(16). HUVEC  cells were  plated (in  four  replicates, 4  x  104 
cells/well in complete medium) on BSA-precoated  48-well plates, 
and IP-10 was added at final concentrations of 0, 15, 45, 135, 400, 
or 1,200 ng/ml. After incubation for 1 h, the supernatant was aspi- 
rated, and the cells  were fixed and stained using Diff-Quick (Baxter 
Scientific Products, McGaw Park, IL). 
Cell Migration Assay.  Cell migration was measured  as described 
(17). Two 2-mm scratches were made in each well of a 6-well plate 
containing confluent HUVEC using a modified  rubber cell scraper. 
The wells were rinsed, and 1.5 ml complete medium containing 
0, 15, 45, 135, 400, or 1,200 ng/ml IP-10 was added. After 24 h 
of incubation, two additional scratches per well were made as ref- 
erence marks, the medium was aspirated, and the cells were fixed 
and stained using Dill-Quick. Cell migration into the scratched 
area was evaluated under an inverted phase microscope. 
Endothelial Tube Formation on Math'gel.  Tube  formation  was evalu- 
ated as described (18). Matrigel (320 gl/well), used at 4~  to coat 
a 24-well  plate, was allowed  to polymerize  at 37~  for 2 h. HUVEC, 
4-6  x  104 cells/well, in a final vol of 1 ml HUVEC complete 
medium containing 0, 15, 45,135,400,  or 1,200 ng/ml IP-10, were 
plated on the Matrigel substratum. After an 18-h incubation, the 
medium was aspirated, and the adherent cells  were fixed  and stained 
using Diff-Quick. Tube formation was examined  visually,  and total 
tube area per well was quantitated by the digital analyzer.  The assay 
was performed in duplicate. 
Statistical Analysis.  Arithmetic means, standard deviations, and 
Student's t tests were calculated by conventional formulas using 
Systat for the Macintosh (Systat Inc., Evanston, IL). 
Results 
IP-IO Inhibits Neovascularization In Viva  To assess the effects 
of IP-10 on neovascularization in vivo, we have used a mouse 
model in which subcutaneous injection of Matrigel impreg- 
nated with bFGF rapidly induces new vessel formation (15). 
The results of a representative experiment in which groups 
of athymic mice were injected either with Matrigel alone (0.5 
ml) (Fig.  1 A); Matrigel (0.5  ml) plus bFGF (150 ng/ml) 
(Fig. 1 B), or Matrigel (0.5 ml) plus bFGF (150 ng/ml) plus 
IP-10 (400 ng/ml) (Fig.  1 C) are depicted in Fig. 1. Micro- 
scopic examination of the Matrigel plugs removed from the 
mice 7 d after injection revealed the presence of only a few 
endothelial cells invading the Matrigel alone plug (A).  In 
contrast, abundant endothelial cells, often organized to form 
blood vessels containing red blood cells, were present in the 
Matrigel plus bFGF plug (B). Addition of IP-10 to Matrigel 
plus bFGF resulted in marked reduction in the number of 
endothelial cells invading the plug and the absence of blood 
vessels (C). Quantitative analysis of this experiment, which 
included five nude mice per treatment group, is shown in 
Fig.  1 D. Plugs of Matrigel alone contained very few endo- 
thelial cells (mean surface area 483.8  x  103 #m2).  Matrigel 
plugs impregnated with bFGF contained •13-fold  more cells 
compared with plugs of Matrigel alone (mean surface area 
6,511.2  x  103 gm2). Matrigel plugs with IP-10 added to- 
gether with bFGF contained significantly fewer cells com- 
pared  to  Matrigel  plus  bFGF  plugs  (mean  surface  area 
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Figure  1.  Effect  of IP-10 on neovascularization  in vivo. Groups of five 
female BALB/c  nu/nu mice were injected subcutaneously  with Matrigel 
alone, Matrigel plus bFGF, or Matrigel plus bFGF and IP-10. Plugs were 
removed 7 d after injection, and histologic sections were stained with 
Masson's trichrome. (A) Histology (x400) of a representative Matrige] 
alone plug, (B) Matrigel plus bFGF plug, and (C) Matrigel plus bFGF 
and IP-10 plug. In A, B, and C, the left margin coincides with the edge 
of the plug. (D) Quantification of angiogenesis. Results are expressed as 
mean Matrigel surface  area (x 103/~m  2) occupied by cells, as determined 
by a semiautomated digitalized analyzer. Each dot represents the mean 
surface area (x 103 /~m  2) for each mouse and  reflects 15 readings on 
nonoverlapping Matrigel fields. 
2,568.0  x  103  /~m  ~,  P  =  0.0002).  These  experiments 
demonstrated that IP-10 can act as a potent inhibitor ofbFGF- 
induced neovascularization  in vivo. 
We  wished  to  confirm  these  observations  and  to  test 
whether  other cytokines/chemokines might  also  act as in- 
hibitors of neovascularization measured by this in vivo assay 
system. As shown in Table 1, IP-10 consistently inhibited neo- 
vascularization of Matrigel  plugs  containing bFGF.  When 
added to Matrigel alone, without bFGF, IP-10 had at most 
a  slight  inhibitory  effect.  Mig  and  Ib8,  two  additional 
members of the ol chemokine family, had little or no inhibi- 
tory effect on angiogenesis induced by bFGF and Matrigel. 
R.ANTES and MCAF, members of the B chemokine family, 
had no inhibitory effect on neovascularization induced by bFGF 
and Matrigel. As reported (15), TGF-B had little or no effect 
on neovascularization in this assay system. These experiments 
demonstrated that IP-10 can be a potent inhibitor of neovas- 
cularization induced by bFGF in vivo, and they suggest that 
inhibition of angiogenesis is not common to all chemokines. 
Effects of lP-lO on Endothelial Cell Proliferation, Attachment, 
Migration and Differentiation.  Angiogenesis is known to be 
a complex process that requires endothelial cell proliferation, 
migration, and differentiation into tubelike structures (1). Since 
IP-10 inhibited  angiogenesis  in vivo, we wished  to dissect 
its mode of action. First, we tested whether IP-10 can inhibit 
endothelial cell proliferation. HUVEC and FBHE are growth 
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In  Vivo 
Additions to 
Matrigel  Mean  surface  area  _+ SD 
x I03/~m 2 
None  554  196 
bFGF  5,511  1,404 
bFGF  +  IP-10  1,317  389 
IP-IO  355  128 
None  484  209 
bFGF  6,511  1,097 
bFGF  +  IP-10  2,568  769 
bFGF  +  TGF-/3  9,131  2,113 
None  997  34 
bFGF  7,060  820 
bFGF  +  IP-10  2,118  447 
bFGF  +  IL-8  5,662  867 
bFGF  +  Mig  6,303  824 
None  665  152 
bFGF  6,140  854 
bFGF  +  IP-IO  1,826  858 
bFGF  +  P,  ANTES  5,856  657 
bFGF  +  MCAF  6,196  820 
BALB/c nu/nu female mice (five mice per condition in each experiment) 
were injected subcutaneously with either Matrigel alone (0.5 ml), Matrigel 
plus bFGF (150 ng/ml), Matrigel plus IP-IO (400 ng/ml), or Matrigel 
plus bFGF (150 ng/ml) plus one of the indicated cytokine/chemokines 
(all at 400  ng/ml).  The  Matrigel plugs were removed after 7 d  and 
processed for histology. The results reflect the mean Matrigel surface area 
occupied  by cells (-+  SD) for each group of mice. 
factor-dependent primary endothelial cell cultures found to 
grow optimally in vitro with ECGS and bFGF, respectively. 
The murine heart endothelioma cell line H5V and the mu- 
fine pulmonary microvascular endothelial cell line CD3-21 
are immortalized, growth factor-independent endothelial cell 
lines.  IP-10  (400 ng/ml)  had little  or no effect on growth 
factor (bFGF or ECGS)-induced or spontaneous endothelial 
cell proliferation when measured after 7 d of culture (Table 
2).  Also,  IP-10  had  little  or  no  effect on  growth  factor- 
induced HUVEC proliferation when measured after 30 h of 
culture,  even at 2/xg/ml and in the absence of heparin.  As 
expected,  TGF-~  inhibited  bFGF-induced  proliferation  of 
FBHE cells,  and PF-4, in the absence of heparin,  inhibited 
the proliferation of HUVEC at 40 gg/ml but not at 2 gg/ml. 
Time course experiments (not shown) confirmed that IP-10 
failed to inhibit endothelial cell proliferation at 1, 3, and 5 d. 
Dose response experiments (not shown) demonstrated that 
IP-10 failed to inhibit endothelial cell growth at doses ranging 
between 10 ng/ml and 2 ttg/ml. Thus, IP-10 is not an inhib- 
itor of endothelial cell growth in vitro, suggesting that inhi- 
bition of cell division is not the mechanism by which IP-10 
inhibits  angiogenesis in vivo. 
To assess whether IP-IO interferes with the migration and 
attachment  of endothelial  cells,  HUVEC cells were tested 
for their ability to attach to BSA-coated plastic wells (16) and 
to migrate (17), in the presence or absence of IP-10 (15-1,200 
ng/ml). As measured in these assays, neither endothelial cell 
attachment nor migration was affected by IP-10 at all tested 
doses (results not  shown). 
We next tested whether IP-10 inhibits the differentiation 
of endothelial cells into tubelike structures, an essential step 
to new blood vessel formation (16). As reported (16), when 
endothelial cells (HUVEC) were cultured for 12-18 h on a 
Matrigel substrate, they rapidly aligned with one another and 
formed an intricate  network of tubelike structures  (Fig.  2 
A). In the presence of IP-IO, the endothelial cells formed small 
aggregate structures, and the network of tubelike structures 
was strikingly less extensive than  in control cultures  (Fig. 
2 B). This effect of IP-10 was not due to inhibition  of en- 
dothelial cell attachment  to the Matrigel  monolayer or to 
inhibition  of cell survival and proliferation during incuba- 
tion, because, at the end of culture, with or without IP-10, 
both  similar  numbers of nonadherent  cells were recovered 
(~10%  of the initial input),  and similar numbers of nuclei 
were counted on the Matrigel monolayer. Measurement of 
the  total  tube  area  by  a  semiautomated  digital  analyzer 
confirmed the visual observation that IP-IO inhibits endothelial 
cell differentiation into tubelike structures (Fig.  3 C). This 
effect was dose dependent, and the surface area reduction was 
significant at all IP-10 doses tested (P -.<0.001). These experi- 
ments demonstrated that IP-10 inhibits endothelial  cell differen- 
tiation into capillarylike structures in vitro and suggested a 
mechanism whereby IP-10 could inhibit angiogenesis in vivo. 
Discussion 
We have shown that human IP-lO is a potent inhibitor of 
angiogenesis in vivo. When bFGF, an angiogenic factor, was 
added to Matrigel and injected subcutaneously into mice, a 
vigorous local angiogenic response was induced.  However, 
when IP-10 was added to bFGF-containing Matrigel, the an- 
giogenic response was markedly reduced.  In vitro  testing 
showed that IP-10 does not inhibit endothelial cell prolifera- 
tion occurring either spontaneously or after induction by bFGF 
or ECGS, nor does it inhibit endothelial cell attachment and 
migration.  However, IP-IO dose dependently inhibited  en- 
dothelial cell differentiation  into branching networks of tubular 
structures in vitro, a complex process requiring interaction 
of endothelial cells with components of the extracellular ma- 
trix (16). These findings demonstrated that IP-10 is an inhib- 
itor of angiogenesis and suggested that IP-10 suppresses en- 
dothelial cell differentiation  into capillary structures. 
IP-10, a member of the c~ chemokine family, was initially 
described as an immediate early gene induced by IFN-3, in 
the histiocytic lymphoma cell line U937 (19). Activated human 
mononuclear cells, keratinocytes, fibroblasts,  endothelial cells, 
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Proliferation* 
Additions  to culture  Experiment  1  Experiment  2 
cpm/culture 
FBHEr 
Medium  1,094  1,294 
bFGF  8,667  10,664 
bFGF + IP-10 (400 ng/ml)  8,298  9,421 
bFGF + TGF-~/ (10 ng/ml)  193  315 
H5V* 
Medium  71,753  116,102 
Medium + IP-10 (400 ng/ml)  70,148  108,276 
Medium + TGF-/3 (10 ng/ml)  n.d.  72,548 
CD3-21r 
Medium  755  695 
Medium + IP-10 (400 ng/ml)  833  754 
Medium + TGF-B (10 ng/ml)  724  n.d. 
HUVEC* 
Medium  253  191 
ECGS  8,648  7,965 
ECGS + IP-10 (400 ng/ml)  6,315  8,050 
ECGS + TGF-~ (10 ng/ml)  6,441  7,138 
HUVEC~ 
Medium  254  395 
ECGS  1082  915 
ECGS + IP-10 (2/zg/ml)  1092  1784 
ECGS + PF4 (2 #g/ml)  979  674 
ECGS + PF4 (40 /xg/ml)  406  546 
* [3H]Thymidine  was added during the final 18 h of culture. The results are expressed  as mean cpm of triplicate cultures (SDs within 12% of the 
mean), n.d., not done. 
* The endothelial cells/cell lines FBHE, HUVEC, H5V, and CD3-21 (1  x  103 cells/0.2 ml well) were cultured for 7 d with or without IP-10 
or TGF-~. 
S  HUVEC (8  x  103 cells/0.2 ml well) were cultured without heparin for 30 h with or without IP-10 or PF-4. 
and T cells also express the IP-10 gene (19). Both the human 
IP-10 gene and the presumed murine homologue, crg-2, code 
for a secreted mature protein with a predicted molecular mass 
of •8.6  and 8.7 kD, respectively (20, 21). Originally thought 
to be involved in inflammatory processes because of its in- 
ducibility by IFN-3' and  structural  similarity to PF-4 and 
B-thromboglobulin, IP-10 appears  to be multifunctional. It 
inhibited in vitro colony formation by human bone marrow 
hematopoietic cells (22) and exerted a potent antitumor effect 
in vivo (23). Recently, IP-10 was reported to be a chemoat- 
tractant for human monocytes and activated T  lymphocytes 
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and to promote T cell adhesion to endothelial cells (24). How- 
ever, IP-10 has not been found previously to act as an inhib- 
itor of angiogenesis. 
It is of interest that IP-10 inhibited angiogenesis in vivo 
and endothelial cell differentiation in vitro without inhibiting 
endothelial cell proliferation in vitro. Fumagillin, a product 
of Aspergillusfumigatusfresenious  (10); AGM-1470, a synthetic 
homologue of fumagillin (10); thrombospondin (4), a ma- 
trix glycoprotein secreted by a variety of cell types; and the 
recently identified angiostatin,  a fragment of plasminogen 
(25), have all been shown to potently inhibit endothelial cell 2.0 
1.8 
1.6" 
1.4- 
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1.0 ~ 
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Figure  2.  Effect  of It)-10 on endothelial  cell differentiation.  HUVEC 
cells (6  x  104) were plated on Matrigel-coated  24-well plates in either 
complete  medium  alone  or in complete  medium  supplemented  with IP-10 
(15-1,200 ng/ml). After  an 18-h incubation, the cells were stained  with 
Diff-Quick. (A) Microscopic  morphology  (￿  of HUVEC cultured 
in medium alone, and (B) in medium supplemented  with 1,200 ng/ml 
IP-10. (C) Measurement  of the area occupied  by tubelike  structure  using 
a semiautomated  digitalized  analyzer.  The results  reflect  the mean  (_+ SD) 
of 10 separate experiments. 
proliferation in vitro and to suppress  angiogenesis in vivo. 
But TGF-~, a potent inhibitor of endothelial cell prolifera- 
tion in vitro, does not inhibit, and perhaps stimulates, an- 
giogenesis in vivo (3,  15). IFN-ot, the first angiogenesis in- 
hibitor to reach clinical trials, has produced beneficial results 
in the treatment of certain hemangioendotheliomas (26), but 
the mechanisms by which it acts are poorly understood. A 
multistep and complex process such as angiogenesis is likely 
to be under multiple regulatory controls. Inhibition of an- 
giogenesis in vivo by a drug may or may not be the result 
of a direct inhibition of endothelial cell  growth. 
One of the first  angiogenesis inhibitors to be identified 
was  PF-4  (8),  which,  like  II)-10,  is  a  member  of the  ot 
chemokine family. In vitro, PF-4 is a potent inhibitor of  growth 
factor-dependent endothelial cell proliferation (HUVEC), al- 
beit at high (~25 #g/ml) concentrations. Another member 
of the ot chemokine family, IL-8, was reported to stimulate 
umbilical vein endothelial cell proliferation in vitro and to 
be potently angiogenic in vivo (27,  28).  The observations 
that II:8 acts as an angiogenic factor and that PF-4 and IP-10 
act as inhibitors of angiogenesis suggest that, among chemo- 
kines, stimulators and inhibitors of angiogenesis might seg- 
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regate with the presence or absence of  the Glu-Leu-Arg motif. 
IL-8 is representative of the subset of oe chemokines that con- 
tain a Glu-Leu-Arg motif near their NH2  termini (29),  a 
motif absent in both PF-4  and II)-10 (29).  It is of interest 
that we found human Mig not to be an inhibitor of angio- 
genesis, because human Mig also lacks the Glu-Leu-Arg motif 
(30). Thus, inhibition of angiogenesis in the Matrigel assay 
is not a property shared among members of any of the recog- 
nized subsets of the chemokine superfamily. 
Tumor cells are dependent upon new vessel formation to 
grow locally and metastasize (1,  2).  In some cases, tumor 
cells themselves are potently angiogenic, partly because  of 
their failure to secrete factors that inhibit angiogenesis while 
continuing the secretion of factors that stimulate angiogen- 
esis (25). The observation that genetically engineered tumor 
cells that produce high levels of IP-10 lost their tumorige- 
nicity (23) raises the possibility that this phenotypic switch 
might be attributable, in part, to the antiangiogenic effect 
of IP-10. The newly described biological property of It)-10 
to  inhibit  angiogenesis  suggests  the  possibility that  this 
chemokine might be considered as a potential anticancer ther- 
apeutic for future clinical development. 
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